Evidence map›Paper›PMID 36459360›Full record

ArticleInternational journal of hematology2023

Splenectomy as an effective treatment for macrothrombocytopenia in Takenouchi-Kosaki syndrome.

Shio Yamano, Akihiro Iguchi, Kotaro Ishikawa, Atsushi Sakamoto, Toru Uchiyama, Kumiko Yanagi, Tadashi Kaname, Shinji Kunishima, Akira Ishiguro

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Shio YamanoCenter for Postgraduate Education and Training, National Center for Child Health and Development (NCCHD), 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Akihiro IguchiDivision of Hematology, NCCHD, Tokyo, Japan.
Kotaro IshikawaCenter for Postgraduate Education and Training, National Center for Child Health and Development (NCCHD), 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Atsushi SakamotoDivision of Hematology, NCCHD, Tokyo, Japan.
Toru UchiyamaDepartment of Human Genetics, NCCHD, Tokyo, Japan.
Kumiko YanagiDepartment of Genome Medicine, NCCHD, Tokyo, Japan.
Tadashi KanameDepartment of Genome Medicine, NCCHD, Tokyo, Japan.
Shinji KunishimaDepartment of Medical Technology, School of Health Sciences, Gifu University of Medical Science, Gifu, Japan.
Akira IshiguroCenter for Postgraduate Education and Training, National Center for Child Health and Development (NCCHD), 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan. ishiguro-a@ncchd.go.jp.ORCID http://orcid.org/0000-0002-3896-5313
National Center For Child Health and Development · JPGifu University of Medical Science · JP

Funding

Japan Agency for Medical Research and Development 18ek0109366h0001Japan Agency for Medical Research and Development 19ek0109366h0002Japan Agency for Medical Research and Development 20ek0109366h003National Center for Child Health and Development 2021-B3
6 · The paper itself

Abstract

Takenouchi-Kosaki syndrome (TKS) is a rare congenital disease caused by a de novo heterozygous mutation in the CDC42 gene. Its characteristic clinical features are macrothrombocytopenia, developmental delay, dysmorphic facial features, and deafness. Splenectomy has been contraindicated for inherited thrombocytopenia, and there is little information on treatment of macrothrombocytopenia in TKS. In a previously reported case of autoimmune hemolytic anemia (AIHA) with TKS, we observed that AIHA initially resolved with prednisolone, but gradually became refractory to drug therapy. After splenectomy, both anemia and macrothrombocytopenia improved. This is a novel positive effect of splenectomy for thrombocytopenia in TKS, although further studies are required to assess the effectiveness and safety of splenectomy.

Indexed as

Anemia, Hemolytic, AutoimmuneThrombocytopeniaHeterozygoteHumansSplenectomyTreatment OutcomeAutoimmune hemolytic anemiaCDC42MacrothrombocytopeniaSplenectomyTakenouchi-Kosaki syndrome

Identifiers

PMID36459360
OpenAlexW4310600903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.